- 相關(guān)推薦
SiRNA穩(wěn)定抑制肝癌細胞hTERT基因的表達
【關(guān)鍵詞】 肝腫瘤Stable inhibition of hTERT gene by siRNA in hepatocarcinoma cells
【Abstract】 AIM: To elucidate the timeefficiency relation of stable inhibition of hepatocarcinoma cell proliferation by RNA interference in vitro. METHODS: The stable screeninginhibition technique of RNAi was adopted to suppress the expression of hTERT stably. After small hairpin RNA (shRNA) targeting hTERT gene was designed, recombinant vector pGenesilshRNAhTERT was constructed and transfected into hepatocarcinoma SMMC7721 cells, which were stably selected by G418 to establish hepatocarcinoma cell lines stablely expressing pGenesilshRNAhTERT. Realtime RTPCR, MTT and PCRTRAP were utilized to detect the alterations of hTERT mRNA expressions, telomerase activity and cell proliferation. RESULTS: The effectiveness of RNAi existed continually and stably in hepatocarcinoma SMMC7721 cells expressing stably pGenesilshRNAhTERT. In the cell lines expressing stably pGenesilshRNAhTERT, hTERT mRNA was obviously suppressed, and the telomerase activities were significantly decreased. Hepatocarcinoma SMMC7721 cell proliferation significantly inhibited in pGenesilshRNAhTERT group compared to that in negative control group. CONCLUSION: RNAi may continually and stably suppress hTERT mRNA expression and carcinoma cell proliferation, which is a potential new approach for antitumor gene therapy.
【Keywords】 RNA interference; liver neoplasms; telomerase
【摘要】 目的： 利用RNA干擾穩(wěn)定篩選抑制技術(shù)，抑制人端粒酶逆轉(zhuǎn)錄酶（hTERT）基因表達，探討靶向hTERT基因RNAi與抑制肝癌細胞增殖的時效關(guān)系. 方法： 設(shè)計靶向hTERT基因的小干擾RNA，構(gòu)建重組表達質(zhì)粒pGenesilshRNAhTERT并導(dǎo)入肝癌SMMC7721細胞株，經(jīng)G418篩選，建立穩(wěn)定表達siRNAhTERT的細胞株. 采用realtime RTPCR、MTT和PCRTRAP法同時檢測pGenesilshRNAhTERT穩(wěn)定抑制組和未處理SMMC7721細胞組hTERT基因表達、端粒酶活性及細胞增殖變化. 結(jié)果： 在穩(wěn)定表達pGenesilshRNAhTERT的SMMC7721細胞株中，RNAi效力持續(xù)、穩(wěn)定存在，hTERT mRNA表達、端粒酶活性明顯降低，瘤細胞增殖被抑制. 結(jié)論： RNA干擾能持續(xù)、穩(wěn)定地抑制靶基因hTERT mRNA表達及腫瘤細胞增殖，是有潛力的基因治療腫瘤新方法.
【關(guān)鍵詞】 RNA干擾；肝腫瘤；端粒，末端轉(zhuǎn)移酶
0引言
端粒酶的異常表達與惡性腫瘤的發(fā)生發(fā)展和預(yù)后密切相關(guān)［1］， hTERT基因在肝癌中的表達陽性率為89.5%［2］. 研究表明hTERT的高表達能通過多分化刺激來抑制細胞凋亡，導(dǎo)致細胞永生化［3］. 我們依據(jù)RNA干擾（RNA interference, RNAi）原理，使用短發(fā)夾樣RNA（small hairpin RNA, shRNA）設(shè)計的RNAiDNA載體方法［4］，以hTERT基因為靶點，構(gòu)建穩(wěn)定表達小干擾RNA(small interfering RNA, siRNA) 的肝癌SMMC7721細胞株，從體外研究siRNA穩(wěn)定、特異誘導(dǎo)hTERT基因轉(zhuǎn)錄后沉默，逆轉(zhuǎn)癌細胞惡性表型的能力，探討RNAi基因治療惡性腫瘤的時效性.
1材料和方法
1.1材料
肝癌SMMC7721細胞株購自上海細胞生物研究所. 質(zhì)粒pGenesil1購自武漢晶賽生物工程技術(shù)有限公司. 限制性內(nèi)切酶BamHⅠ和HindⅢ購自Roche公司,總RNA提取試劑、轉(zhuǎn)染試劑LipofectamineTM2000等分別購自Takara和Invitrogen公司；端粒酶TRAPHyb Kit購自華美生物工程公司. Taqman探針和引物由Takara公司合成，hTERT及內(nèi)參PO的探針和引物序列參照文獻［4］. siRNAhTERT轉(zhuǎn)錄模板由上海博亞公司合成.
1.2方法
shRNA發(fā)夾結(jié)構(gòu)序列長度為69 bp，兩端分別為BamHⅠ, HindⅢ酶切位點，中間為9 bp莖環(huán)序列分隔的反向重復(fù)靶序列，并以6個T作為RNA聚合酶Ⅲ的轉(zhuǎn)錄終止子. 質(zhì)粒構(gòu)建采用BamHⅠ, HindⅢ雙酶切空質(zhì)粒pGenesil1，將shRNAhTERT轉(zhuǎn)錄模板5′AAGTTCCTGCACTGGCTGATG3′（AF 015950 nucleotides 16821702）和陰性對照轉(zhuǎn)錄模板5′AAGCTTCATAAGGCGCATAGC3′ （與人基因無同源性）分別設(shè)計成發(fā)夾結(jié)構(gòu)，定向克隆至該載體上，經(jīng)篩選、酶切鑒定后，進行測序確定，命名為pGenesilshRNAhTERT，陰性對照命名為pGenesilshRNAPK. 質(zhì)粒轉(zhuǎn)染與G418篩選采用LipofectamineTM2000脂質(zhì)體轉(zhuǎn)染法. 操作按說
【SiRNA穩(wěn)定抑制肝癌細胞hTERT基因的表達】相關(guān)文章：
化學(xué)合成siRNA阻斷小鼠骨髓源性不成熟樹突狀細胞GAPDH的表達03-08
bHLH家族基因?qū)TERT啟動子轉(zhuǎn)錄活性的調(diào)節(jié)研究03-30
樹舌多糖GF對HepA瘤細胞C-myc基因表達的影響03-08
談中藥抑制細胞凋亡的研究進展03-18
體外不去T的HLA不合的造血干細胞移植后NK細胞和T細胞上殺傷抑制03-08